Log in to search using one of your social media accounts:

 

Preoperative Management for Phaeochromocytoma/Paraganglioma Preoperative Management for Phaeochromocytoma/Paraganglioma
Find out what the available evidence tells us about the preoperative management of patients with phaeochromocytomas and paragangliomas.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

New study links'mastermind' gene to rare cancer-causing tumor
Scientists have discovered a new " mastermind fusion gene " may be associated with a rare cancer-causing tumor -- pheochromocytomas ( " pheo " ) and paragangliomas -- according to a study. This breakthrough discovery could lead to more precise treatment as well as a better understanding of cancer itself. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 13, 2017 Category: Science Source Type: news

In-depth gene search reveals new mutations, drug targets in rare adrenal tumors
(University of Pennsylvania School of Medicine) Casting one of the largest genomic nets to date for the rare tumors of the autonomic nervous system known as pheochromocytoma and paraganglioma (PCC/PGL) captured several new mutations driving the disease that could serve as potential drug targets, researchers from Penn Medicine and other institutions reported this week in Cancer Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2017 Category: Global & Universal Source Type: news

Pheochromocytoma
Title: PheochromocytomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 9/6/2016 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - September 6, 2016 Category: Cardiology Source Type: news

Study identifies important predictors for PC/PGL
BALTIMORE – Tumor size and the presence of mutations of the succinate dehydrogenase complex subunit B (SDHB) gene may be reliable indicators of prognosis after surgery for pheochromocytoma and... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 13, 2016 Category: Endocrinology Source Type: news

Perioperative Care of PhaeochromocytomaPerioperative Care of Phaeochromocytoma
This article reviews the essentials of perioperative care and monitoring in patients with pheochromocytomas and paragangliomas. BJA Education (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 7, 2016 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Adrenoceptor Blockade for Hormonally Functional Pheo/PGLAdrenoceptor Blockade for Hormonally Functional Pheo/PGL
A new study examines whether patients with hormonally functional pheochromocytomas and paragangliomas (pheo/PGLs) are receiving the appropriate pharmacological treatment. Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Published in Hormone and Metabolic Research, a study found that paediatric patients with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times more likely to also carry a diagnosis of ADHD. Clinical Endocrinology News (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 20, 2016 Category: Endocrinology Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - May 19, 2016 Category: Endocrinology Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Pediatric News)
Source: Pediatric News - May 19, 2016 Category: Journals (General) Source Type: news

Quantification of Metanephrine and Normetanephrine in Urine Using Liquid Chromatography-Tandem Mass Spectrometry
Measuring urinary metanephrines aides in the diagnosis of pheochromocytomas–catecholamine producing tumors. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) allows for greater sensitivity and simpler sample preparation as compared with other techniques. Here we describe a simple LC-MS/MS method for measuring metanephrines in urine. Each urine sample was treated with diphenylboronic acid to create boronate complexes, and then applied to a Bond-Elut Plexa cartridge. After solid phase extraction, samples were concentrated and analyzed on an Atlantis T3 column with chromatographic run time totaling 8.5 min. MS/M...
Source: Springer protocols feed by Imaging/Radiology - November 27, 2015 Category: Radiology Source Type: news

Quantitation of Free Metanephrines in Plasma by Liquid Chromatography-Tandem Mass Spectrometry
We describe here a liquid chromatography-tandem mass spectrometry method to measure free metanephrines in plasma. Free metanephrine and normetanephrine are extracted via solid-phase extraction. After extraction and evaporation, the reconstituted supernatant is analyzed by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The MS/MS is set to selective reaction monitoring mode (180.1 → 148.1 m/z for metanephrine, 183.1 → 168.1 for d3-metanephrine, 166.1 → 134.1 m/z for normetanephrine, and 169.1 → 137.2 ...
Source: Springer protocols feed by Imaging/Radiology - November 27, 2015 Category: Radiology Source Type: news

Sharpen your USMLE skills with this top missed test prep question
A top priority for medical students is preparing for the United States Medical Licensing Exam (USMLE), which is why each month, we’re giving you an exclusive scoop on the most challenging USMLE questions and expert strategies to help you beat them. This month’s question explores pathophysiology. Think you know the answer? Check out the question that stumped most of your peers—and hear an expert video explanation of the answer from Kaplan Medical. Welcome to the second post in AMA Wire’s series, “Tutor talk: Tips from Kaplan on the most missed USMLE questions.” Each month, we’ll r...
Source: AMA Wire - October 19, 2015 Category: Journals (General) Authors: amamod Source Type: news

Adrenal-Sparing Surgery Better for PheochromocytomaAdrenal-Sparing Surgery Better for Pheochromocytoma
Patients with MEN2 and pheochromocytoma who have adrenal-sparing surgery as opposed to adrenalectomy show similar recurrence rates at 10 years of follow-up, but importantly retain adrenal function. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 27, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Pheochromocytoma Therapeutic Pipeline Review H1 2015 Market Research...
RnRMarketResearch.com adds “Pheochromocytoma – Pipeline Review, H1 2015” to its store. The report provides an overview of the Pheochromocytoma’s therapeutic pipeline.(PRWeb May 20, 2015)Read the full story at http://www.prweb.com/releases/pheochromocytoma-pipeline/review-h1-2015-market/prweb12733418.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 20, 2015 Category: Pharmaceuticals Source Type: news

The CNIO identifies a new gene involved in hereditary neuroendocrine tumors
(Centro Nacional de Investigaciones Oncologicas (CNIO)) Mutations in the MDH2 gene, a key factor in cellular metabolism, are associated with the development of pheochromocytomas and paragangliomas, neuroendocrine tumors that affect the suprarenal and parathyroid glands, respectively. Up to 50 percent of patients inherit and/or transmit susceptibility to developing these tumors. The discovery will enable genetic diagnosis prior to the appearance of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 30, 2015 Category: Cancer & Oncology Source Type: news

Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - September 22, 2014 Category: Pharmaceuticals Source Type: news

Biochemical and radiological features of pheochromocytoma
Pheochromocytomas (PHEOs) are catecholamine-producing neuroendocrine tumours and can cause life-threatening hypertensive crises. An elevation (> 4-fold above the upper limit of normal (ULN)) of fractionated metanephrine (MN) and nor-metanephrine (NMN), collectively called metanephrines (MN and NMN), either in plasma or urine are the most sensitive tests for the diagnosis of PHEO. There are a greater number of false positive results when the elevations are more modest. Kannan et al. retrospectively reviewed the charts of patients with and without PHEO in order to identify biochemical and radiological features in PHE...
Source: Society for Endocrinology - June 26, 2014 Category: Endocrinology Source Type: news

TERT promoter mutations in adrenal tumours
The telomerase reverse transcriptase gene (TERT) is essential for telomere stabilization and cell immortalization. A role for TERT promoter mutations C228T and C250T has been demonstrated in aggressive human cancer. The underlying mechanisms of telomerase activation is not known in adrenal tumors. Liu and colleagues assessed C228T and C250T TERT mutations, finding that TERT promoter mutation C228T is a recurrent event associated with adrenocortical carcinoma, but rarely occurs in paraganglioma or pheochromocytoma. The involvement of the TERT gene in adrenocortical carcinoma is a new finding. Read the full article at Liu e...
Source: Society for Endocrinology - June 26, 2014 Category: Endocrinology Source Type: news

Endocrine Society First to Address Rare Adrenal-Tumor CareEndocrine Society First to Address Rare Adrenal-Tumor Care
New clinical practice guidelines are the first ever to address management of patients with pheochromocytoma and paraganglioma, rare adrenal tumors that can be fatal if not diagnosed. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 5, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Experts recommend blood, urine testing to diagnose rare adrenal tumors
(The Endocrine Society) The Endocrine Society today issued a Clinical Practice Guideline for the diagnosis and treatment of two types of rare adrenal tumors -- pheochromocytomas and paragangliomas -- that can raise the risk of cardiovascular disease and even death if left untreated. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2014 Category: Global & Universal Source Type: news

New Source of Fat Tissue Stem Cells Found
(MedPage Today) -- Islets of brown adipose tissue (BAT) have been identified in the fat deposits surrounding human pheochromocytoma tumors, according to Italian researchers. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 8, 2014 Category: Endocrinology Source Type: news

Exome sequencing in phaeochromocytoma/paraganglioma
In this study, McInerney-Leo et al. have assessed whether whole exome sequencing (WES), using an off-the-shelf exome capture platform rather than designing individual targeted assays, is a sensitive, time- efficient and cost-effective way to offer genetic testing in a population of individuals with established diagnosis of PCC/PGL. They also evaluated the target capture of the currently available exome capture platforms for exons of the known PCC/PGL genes. They demonstrate that WES accurately diagnosed all mutations in all 11 patients with PCC/PGL in whom mutations had been detected previously by Sanger sequencing. Furth...
Source: Society for Endocrinology - January 27, 2014 Category: Endocrinology Source Type: news

Exome sequencing in phaeochromocytoma/paraganglioma
In this study, McInerney-Leo et al. have assessed whether whole exome sequencing (WES), using an off-the-shelf exome capture platform rather than designing individual targeted assays, is a sensitive, time- efficient and cost-effective way to offer genetic testing in a population of individuals with established diagnosis of PCC/PGL. They also evaluated the target capture of the currently available exome capture platforms for exons of the known PCC/PGL genes. They demonstrate that WES accurately diagnosed all mutations in all 11 patients with PCC/PGL in whom mutations had been detected previously by Sanger sequencing. Furth...
Source: Society for Endocrinology - January 24, 2014 Category: Endocrinology Source Type: news

Long-term prognosis in pediatric pheochromocytoma
A third of patients with paraganglial tumors, pheochromocytoma, and paraganglioma, carry germline mutations in one of the susceptibility genes, RET, VHL, NF1, SDHAF2, SDHA, SDHB, SDHC, SDHD, TMEM127, and MAX. Despite increasing importance, data for long-term prognosis are scarce in pediatric presentations. Using the European–American–Pheochromocytoma–Paraganglioma Registry as a platform, Bausch and colleagues report the first and only population-based study of longterm outcomes in pediatric pheochromocytoma. Read the full article at Bausch et al. (2014) Endocrine-Related Cancer 21; 17&nda...
Source: Society for Endocrinology - January 24, 2014 Category: Endocrinology Source Type: news

What Neoplasms are Patients with Neurofibromatosis At Risk For?
Discussion Neurofibromatosis Type 1 (NF1) is one of many neurocutaneous diseases with a probable underestimated incidence of 1:3000. Also called phacomatoses, a review can be found at: What is the Epidemiology and Genetics of the Major Phacomatoses? The key elements of NF1 are: Neurofibromatosis Type 1 Epidemiology: 1:2500-3000 – most common phacomatosis Genetics: autosomal dominant with variable penetrance, associated with chromosome 17 Neurological: various central nervous system tumors especially neurofibromas (often benign but may act malignant because of location or size, tumors may also degenerate into a mal...
Source: PediatricEducation.org - September 23, 2013 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

What Neoplasms are Patients with Neurofibromatosis At Risk For?
Discussion Neurofibromatosis Type 1 (NF1) is one of many neurocutaneous diseases with a probable underestimated incidence of 1:3000. Also called phacomatoses, a review can be found at: What is the Epidemiology and Genetics of the Major Phacomatoses? The key elements of NF1 are: Neurofibromatosis Type 1 Epidemiology: 1:2500-3000 – most common phacomatosis Genetics: autosomal dominant with variable penetrance, associated with chromosome 17 Neurological: various central nervous system tumors especially neurofibromas (often benign but may act malignant because of location or size, tumors may also degenerate into a mal...
Source: PediatricEducation.org - September 23, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news

Gene susceptibility testing in phaeochromocytoma and paraganglioma
Recent studies have suggested that around one-third of individuals with phaeochromocytoma or paraganglioma have an inherited genetic predisposition, prompting some calls for genetic testing in all patients with phaeochromocytoma or paraganglioma. Such a strategy is expensive, and variation between populations is large. Jafri and colleagues analysed data from a 10-year period in the West Midlands PPGL/HNPGL database, finding that clinical risk factors (positive family history, multiple tumours, earlier age at onset) could be used to target genetic testing in a cost-effective manner, though universal testing would be require...
Source: Society for Endocrinology - June 12, 2013 Category: Endocrinology Source Type: news

What Causes Hypercalcemia?
Discussion Calcium homeostasis is regulated by mechanisms involving the absorption from the gastrointestinal tract, bone deposition and resorption, and renal excretion. To review Vitamin D homeostasis click here. Serum calcium is found in three forms: free (47%), protein bound (43%) and diffusable calcium complexes (10%). The protein binding proteins are albumin (80%) and globulin (20%). The free calcium is the most important biologically. Acidosis also increases free calcium and alkalosis decreases free calcium. Problems associated with hypercalcemia include nausea, emesis, abdominal pain, constipation, polyuria, dehydra...
Source: PediatricEducation.org - March 25, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news

How Common Are Skeletal Problems in Neurofibromatosis Patients?
Discussion Neurofibromatosis Type 1 (NF1) is one of many neurocutaneous diseases. Also called phacomatosis, a review can be found at: What is the Epidemiology and Genetics of the Major Phacomatoses? The key elements of NF1 and 2 are: Neurofibromatosis Type 1 Epidemiology: 1:2500-3000 – most common phacomatosis Genetics: autosomal dominant with variable penetrance, associated with chromosome 17 Neurological: various central nervous system tumors especially neurofibromas (often benign but may act malignant because of location or size, tumors may also degenerate into a malignant variant or cause other problems such a...
Source: PediatricEducation.org - February 4, 2013 Category: Pediatrics Authors: Donna M. D'Alessandro, M.D. Tags: Uncategorized Source Type: news

Level of tumor protein indicates chances cancer will spread
Contact: Robert Bock or Marianne Glass Miller 301-496-5133 Level of tumor protein indicates chances cancer will spread NIH researchers seek to develop test to guide treatment Researchers at the National Institutes of Health and the University of Hong Kong have discovered that high levels of a particular protein in cancer cells are a reliable indicator that a cancer will spread. By measuring the protein’s genetic material in tumors that had been surgically removed from patients, along with measuring the genetic material from surrounding tissue, the researchers could predict at least 90 percent of the time whether a c...
Source: Kidney Cancer Association - February 2, 2011 Category: Urology & Nephrology Source Type: news